{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antibodies+Bispecific", "query": { "condition": "Antibodies Bispecific" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 184, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antibodies+Bispecific&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T20:16:00.891Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06826768", "title": "A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "REGN5678", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2025-07-09", "completion_date": "2029-05-01", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-06-26T20:16:00.891Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06826768" }, { "nct_id": "NCT02892123", "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-expressing Cancers" ], "interventions": [ { "name": "ZW25 (Zanidatamab)", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 279, "start_date": "2016-09-30", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-06-26T20:16:00.891Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02892123" }, { "nct_id": "NCT04986865", "title": "A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Mature B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "ATG-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Antengene Biologics Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2021-12-15", "completion_date": "2025-01-31", "has_results": false, "last_update_posted_date": "2025-06-09", "last_synced_at": "2026-06-26T20:16:00.891Z", "location_count": 3, "location_summary": "San Francisco, California • St Louis, Missouri • Philadelphia, Pennsylvania", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04986865" }, { "nct_id": "NCT02173093", "title": "Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Disseminated Neuroblastoma", "Recurrent Neuroblastoma" ], "interventions": [ { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "GD2Bi-aATC", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "BIOLOGICAL" }, { "name": "laboratory evaluations of immune responses", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Months", "maximum_age": "29 Years", "sex": "ALL", "summary": "13 Months to 29 Years" }, "enrollment_count": 40, "start_date": "2014-11", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2019-01-29", "last_synced_at": "2026-06-26T20:16:00.891Z", "location_count": 3, "location_summary": "Detroit, Michigan • New York, New York • Charlottesville, Virginia", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02173093" }, { "nct_id": "NCT04649359", "title": "MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab (PF-06863135)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 187, "start_date": "2021-02-02", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-06-26T20:16:00.891Z", "location_count": 21, "location_summary": "Beverly Hills, California • Irvine, California • Los Angeles, California + 12 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04649359" }, { "nct_id": "NCT04626635", "title": "A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "REGN7075", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Platinum-based doublet chemotherapy", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Trifluridine-tipiracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 933, "start_date": "2020-12-21", "completion_date": "2027-04-07", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-06-26T20:16:00.891Z", "location_count": 21, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04626635" }, { "nct_id": "NCT06585891", "title": "Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "VRC-HIVMAB0121-00-AB", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 24, "start_date": "2024-10-07", "completion_date": "2025-09-30", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-06-26T20:16:00.891Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06585891" }, { "nct_id": "NCT03922204", "title": "A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Solid Tumor, Adult", "B-cell Lymphoma, Adult" ], "interventions": [ { "name": "MCLA-145", "type": "DRUG" }, { "name": "Pembrolizumab (Keytruda)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merus B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2019-05-08", "completion_date": "2024-11-07", "has_results": false, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-06-26T20:16:00.891Z", "location_count": 3, "location_summary": "La Jolla, California • Boston, Massachusetts • New York, New York", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03922204" }, { "nct_id": "NCT03038230", "title": "MCLA-117 in Acute Myelogenous Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "MCLA-117 bispecific antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merus B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2016-04", "completion_date": "2021-05-11", "has_results": false, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-06-26T20:16:00.891Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03038230" }, { "nct_id": "NCT05788484", "title": "A Study of CDX-585 in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Gastric Cancer", "Head and Neck Cancer", "Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Bladder Urothelial Carcinoma", "Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Renal Cell Carcinoma", "Cholangiocarcinoma", "Pancreatic Cancer", "Other Solid Tumors" ], "interventions": [ { "name": "CDX-585", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-05-11", "completion_date": "2025-05-21", "has_results": false, "last_update_posted_date": "2025-06-15", "last_synced_at": "2026-06-26T20:16:00.891Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Celebration, Florida • New York, New York + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Celebration", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05788484" } ] }